Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, & Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Itraconazole (Primary)
- Indications Allergic bronchopulmonary aspergillosis
- Focus Adverse reactions
- Sponsors Pulmatrix
- 07 Aug 2020 According to a Pulmatrix media release, Due to past enrollment delays, coupled with the impact of the COVID-19 pandemic on enrollment, the company with partner Cipla has decided to end this study. They are leveraging this pause in the development program to prepare for a new Phase 2b study of longer study duration and inclusion of efficacy endpoints that are intended to better inform and propel the program forward.
- 14 Jul 2020 Status changed from suspended to discontinued.
- 14 May 2020 Status changed from recruiting to suspended acccording to a Pulmatrix media release.